Allife Medical Science and Technology Co., Ltd.
Quick facts
Phase 1 pipeline
- Anti-BCMA CAR T cells
- Anti-CD19 iCAR NK Cells · Oncology
CD19-targeting chimeric antigen receptor (CAR) T cells - Anti-CD22 CAR NK Cells · Oncology
Targeting CD22 on B cells - anti-Mesothelin Car NK Cells
- EPC treatment group
- EPCs
- iEPCs
- iHSCs treatment group
- Induction of neural stem cells
- Ips-nsc cells
- islet body
- pd-1 and dc-cik cells
- pd-1 and DC-NK cells
- TABP EIC
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: